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Background: Discrepancies are seen between arguments in favor of and against prescribing 
generic versus brand-name drugs. 
Objective: To provide real-world evidence on treatment persistence, economic and clinical 
outcomes of pregabalin, generic versus brand-name (Lyrica
®
, Pfizer), routinely used to treat 
neuropathic pain (NP) or generalized-anxiety-disorder (GAD). 
Methods: Electronic-medical-records from subjects’ first starting treatment with pregabalin 
between January-2015 and June-2016 were retrospectively analyzed. Persistence, resources 
utilization, and costs were assessed, along with remitter and responder rates. 
Results: 4,860 records were analyzed. Discontinuation was lower with brand-name than with 
generic in NP (adjusted hazard ratio [HR]: 0.70 [95% CI: 0.58–0.85], p<0.001) and GAD patients 
(HR: 0.63 [0.45–0.84], p<0.001). Adjusted mean total costs were lower with brand-name: €1,500 
[1,428–1,573] vs. €2,003 [1,864–2,143] in NP and €1,528 [1,322–1,734] vs. €2,150 [1,845–2,454] 
in GAD (both p<0.001). More patients were remitters or responders with brand-name in NP (55.0% 
vs. 46.7% and 59.2% vs. 48.4%, respectively; p<0.001) and GAD (58.6% vs. 48.7% and 64.6% vs. 
47.2%, respectively; p<0.001). 
Conclusions: As a consequence of higher persistence in routine practice, patients who first started 
therapy with pregabalin brand-name versus generic showed better pain or anxiety outcomes at a 
lower cost to payers in Spain. 
 
Keywords: neuropathic pain, generalized anxiety disorder, persistence, costs, outcomes, 
effectiveness, payers. 
1. Introduction 
 Peripheral neuropathic pain (pNP), defined by the International Association for the Study of 
Pain (IASP) as pain initiated or caused by a primary lesion or dysfunction of the nervous system, is 
a common symptom of a group or variety of diseases [1]. The estimated prevalence of pNP is 1–
10% of the adult population. This condition accounts for approximately 40% of cases of chronic 
pain [2]. Generalized anxiety disorder (GAD) is characterized by having symptoms of anxiety most 
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days for at least several weeks in a row [3]. Its prevalence is around 2–7% of the general 
population [4]. These two clinical entities entail a great deal of demand and a great many clinical 
repercussions, and they tend to be chronic. Due to the chronic nature of their symptoms and the 
probable associated disability, they may generate considerable direct costs as well as indirect costs 
(productivity loss) for society as a whole [5-8]. Also, these health conditions result in a loss of 
quality of life that affects all aspects of living: family, friends and work. It should be noted that 
many patients are not properly diagnosed, do not receive suitable drug treatment or are prescribed 
lower doses than they should be [9]. 
Drug therapy represents a cornerstone of treatment for these diseases [1,3]. Pregabalin (a 
neuromodulator and gamma-aminobutyric acid analogue) is the only active substance on the 
market indicated in both pNP and GAD [10]. At present, both brand-name and generic 
presentations are available (Lyrica
®
, Pfizer Inc and pregabalin INN, respectively). Generic drugs 
are medicines that are bioequivalent to the original brand-name drug and have the same levels of 
efficacy, safety and quality [11,12]. Factors that may influence their use include physician 
awareness and healthcare intervention strategies with respect to generic drugs [12,13]. 
Discrepancies are seen between arguments in favor of and against prescribing generic drugs [14]. 
Traditionally, the primary advantage of a generic drug was its cost–effectiveness ratio compared to 
its reference drug, as a generic drug coupled a similar expected clinical effect with a lower cost of 
drug acquisition. However, since reference prices were established, this is no longer the case in 
Spain; now, generic and brand-name drugs come at the same cost to the Spanish National Health 
System (SNS) after loss of exclusivity period or patent protection [15]. The disadvantage of a 
generic drug is the confusion it may cause in patients with respect to its commercial name (active 
substance) and its presentation or form (bioappearance), especially in older people [14,16,17]. This 
potential confusion may lead to medication errors, which could in turn lead to treatment non-
adherence, cause a possible decrease in clinical effectiveness, trigger the onset of adverse effects 
and generate a potential increase in associated healthcare costs [18,19]. This change in pill 
appearance (physical characteristics of shape, color, size and packaging that identify medicines) 
which occurs when generic drugs are supplied by different brands over time might result in higher 
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levels of treatment discontinuation or less likely to be adherent [19]. Therefore, administration of a 
generic drug could be considered a factor to be taken into account, particularly in some countries, 
like Spain, where generic substitution is allowed and their governments encourage doctors to 
prescribe them. Pharmacists can make a substitution between generics, choosing one from those 
available in the national system of reference prices, unless the doctor and/or the patient prefer 
another product [15]. 
Treatment persistence constitutes a key factor in disease progression and risk of 
complications. Confirming this hypothesis (link between treatment persistence vs. clinical and 
economic consequences) in both diseases (pNP, GAD) with the same active substance (brand-name 
vs. generic pregabalin) would render the conclusions more robust. While there are other data 
sources, including claims databases, patient registries, internet-based consumer research and 
prescription-based data collection, this article focuses on the evidence with respect to behaviors and 
attitudes collected by the Spanish Health System Research Network (Red de Investigación en 
Servicios Sanitarios, RedISS), a research-based organization which uses electronic medical records 
(EMRs) stored on the OMIAPWIN software application in use at many healthcare centers in Spain. 
This allows for an established method of researching current treatment practices across a wide 
range of disease areas using robust, real-world data that accurately reflect current symptom 
prevalence and severity as well as associated treatment practices for a number of common chronic 
disease areas. This article provides real-world evidence on treatment persistence as well as clinical 
and economic consequences of generic versus brand-name drugs used in routine clinical practice to 





 This paper reports and interprets the findings of a secondary investigational analysis 
conducted by ClinicResearch. This investigational analysis, approved by the Institutional Research 
Board of the Universitat Internacional de Catalunya in Barcelona and the Spanish Agency of 
Medicines, used existing anonymized EMRs linked from the patient database of the RedISS 
Foundation (www.rediss.es). The RedISS Foundation is a nonprofit research network whose 
primary mission is to conduct research on the services provided by healthcare management 
organizations in Spain. RedISS is a longitudinal, anonymized research database of EMRs kept by 
family physicians (FPs) across Spain. The patient data included in the database are stripped of 
identifying details as specified in Spanish Law 15/1999, of 13 December, on Personal Data 
Protection. For the findings presented here, primary care practices in Spain from two regions 
(Catalonia and Asturias) provided patient data in the form of clinical records for over 700,000 
actively registered individuals. The data are representative of the Spanish population. The data 
available in the RedISS database include information on demographics, medical history (including 
diagnoses and health contacts), results of clinical investigations, drug prescriptions and days of sick 
leave. Diagnostic data are recorded using the International Classification of Primary Care version 2 
(ICPC-2) and/or the International Statistical Classification of Diseases and Related Health 
Problems (Ninth Revision) codes [20]. The RedISS database contains data on hospitalizations and 
emergency room visits from reference regional and tertiary health centers for such FPs and their 
corresponding primary care centers. The RedISS database also contains information on pharmacy 
drug supply through its regional pharmacy drug supply database link.  
 
2.2 Patient and Public Involvement 
Patients or public were not involved in this work directly, but EMRs were abstracted from the 
database to carry out the analysis. The EMRs of patients with either pNP or GAD were identified in 
the RedISS database based on patients’ medical and treatment history. Patients’ first prescribed 
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pregabalin (brand-name or generic) between January 1, 2015, and June 30, 2016, were eligible to 
enroll. The inclusion criteria were as follows: male or female, 18 years of age or older, having been 
entered in the database 12 or more months before first being prescribed pregabalin, having been 
enrolled in the long term prescription follow up program at each healthcare center, having received 
≥ 2 prescriptions for generic or brand-name pregabalin (depending on the analysis group assigned) 
and having been diagnosed with pNP or GAD in the 180 days before the date of enrollment, with at 
least 2 follow-up contacts in the database. Patients first prescribed pregabalin after June 30, 2016, 
and patients who might have been exposed to pregabalin within 12 months of the index date were 
excluded. Patients who received combination therapy with concomitant or sequential generic or 
brand-name pregabalin were considered ineligible for the analysis. The EMRs of patients whose 
healthcare was transferred out to other regions or healthcare centers during the follow-up period 
were also excluded. The EMRs of patients with concomitant pNP and GAD were excluded to 
prevent bias in estimating healthcare resource utilization and/or days of sick leave. From these data, 
four subgroups of therapeutic regimens were identified according to the Anatomical Therapeutic 
Chemical (ATC) Classification System, N03AX16 [21]: brand-name pregabalin for pNP, generic 
pregabalin for pNP, brand-name pregabalin for GAD and generic pregabalin for GAD. The index 
date was defined as the date on which a patient was first prescribed either brand-name or generic 
pregabalin in either the pNP group or the GAD group. Patients were followed up until the earliest 
date among the following options: the index date plus 12 months; the end of recorded data; the last 
prescription for the regimen of interest plus 30 days; or the date of regimen change. The end of 
recorded data was defined as the earlier date between the last date on which data was collected for 
the practice or the date of death. 
The initial analysis plan included obtaining all available records that met all screening criteria 
in the enrollment period (from the index date). However, an initial predetermination of the 
minimum sample size was also performed. This because it was considered to have an initial 
estimation of the minimum sample size in each of the analyzed groups needed to achieve a 
sufficient statistical power, and also sufficient to calculate the effect sizes (magnitude of 
differences observed) to have a minimum clinical significance. Thus, the sample size was 
 
 7 
calculated based on finding a minimum difference of €250 (standard deviation [SD]: €1000) 
between the brand-name drug and the generic drug in terms of non-adjusted healthcare costs, both 
in pNP and in GAD. These differences enabled detection, with an α error < 0.05 and a β error 
< 0.15 (85% statistical power), of differences of at least a small magnitude according to Cohen’s d 
with a minimum effect size of 0.25 [22]. Given these parameters, it was estimated that there should 
recruit at least 300 medical records to each of the four groups. 
  
2.3 Diagnosis and demographics 
The records of subjects with pNP or GAD included in the database are habitually obtained 
according to the International Classification of Primary Care (ICPC-2) [20], codes N92-N99 or 
P74, and/or the International Classification of Diseases (Ninth Revision), Clinical Modification 
(ICD-9-CM; codes 350.1, 352.9, 353.1, 353.3, 353.8, 354.0, 355.1, 355.5, 357.2, 357.4, 357.8, 
357.9, 053.13 or 300.02, respectively). The criteria followed were in all cases at the physician’s 
discretion. pNP was considered to be pain initiated or caused by a primary lesion or dysfunction of 
the peripheral nervous system (nerve roots, nerve plexi or nerves)[1]. GAD was considered to be 
symptoms of anxiety most days for at least several weeks in a row. These symptoms had to include 
excessive worrying, muscle tension and autonomic hyperarousal [3]. 
The following demographic variables and comorbidities were considered to be extracted from 
the database: age (continuous and by range), sex and time since diagnosis (years), as well as prior 
history based on the ICPC-2 of hypertension (K86, K87), diabetes mellitus (T89, T90), obesity 
(T82), active smoking (P17), alcoholism (P15, P16), all types of organ failure (heart, liver and 
kidney), ischemic heart disease (codes: K74, K76, K75), cerebrovascular accident (K90, K91, 
K93), dementia (P70), depressive syndrome (P76) and malignant neoplasms (all types: A79, B72-
75, D74-78, F75, H75, K72, L71, L97, N74-76, T71-73, U75-79, W72-73, X75-81, Y77-79). The 
following were also used for each patient cared for as a summary variable of general comorbidity: 
a) the Charlson comorbidity index [23], b) the number of chronic comorbidities and c) the case-mix 
index, based on adjusted clinical groups (ACGs), a system for classifying patients by resource 





Medication was obtained according to the ATC classification [21]: a) pregabalin (active 
substance) and b) concomitant medication: non-steroidal anti-inflammatory drugs (NSAIDs, M01), 
opioids (N02A), analgesics (N02B), sedatives/hypnotics (anxiolytics: N05C) and antidepressants 
(N06A). The information was obtained from the drug supply records for drugs. The choice of 





 The adherence rate was defined according to the criteria of the International Society for 
Pharmacoeconomics and Outcomes Research (ISPOR) and calculated based on use/medication 
possession ratio (MPR) and treatment persistence [25]. MPR was assessed from the first to the last 
prescription and represents the number of days of medication supplied divided by the number of 
treatment days (from the index date). Persistence was defined as the time, measured in days, 
without stopping the initial treatment or switching to another medication at least 30 days after the 
initial prescription. It is expressed as the difference between the date of first supply (enrollment) 
and the date of last supply, plus the number of days that would be covered by the last supply (30 
days).  
 
2.5.2 Resource utilization and cost analysis 
 The societal and the National Health System (NHS) perspectives were taken into account to 
compute healthcare and indirect costs. Healthcare costs (direct costs) were considered to be those 
relating to healthcare activity (medical visits, days of hospitalization, emergency visits, diagnostic 
and therapeutic requests, etc.) performed by healthcare professionals. Non-healthcare costs 
(indirect costs) were considered to be those relating to work productivity loss (days of sick leave 
due to temporary disability). Cost was expressed as mean cost per patient (average per unit) 
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throughout the analysis period (1 year). Unitary costs applied were as follows: primary care 
medical visit; €23.19, emergency room visit; €117.53, hospitalization (one day); €420.90, 
specialized care medical visit (neurology, orthopedic, psychiatry or internal medicine departments); 
€92.00, day hospital session; €125.55, laboratory tests; €22.30, single x-ray; €18.50; and 
diagnostic/therapeutic tests (related to peripheral neuropathic pain and generalized anxiety 
disorder); €37.12.  Prices were based on the sites’ analytical accounting, except medication and 
days of sick leave. Prescriptions were quantified by retail price per pack at the time of prescription 
(according to the Drug Catalogue of the General Council of Associations of Official Pharmacists of 
Spain. Available at: https://botplusweb.portalfarma.com/botplus.aspx). Concomitant medication 
(non-steroidal anti-inflammatory drugs, opioids, analgesics, anxiolytics and antidepressants) was 
also included in calculating costs. Days of occupational disability and productivity losses were 
quantified according to the average interprofessional wage (source: Spanish Statistical Office 
[Instituto Nacional de Estadística, INE]) [26]. Cost per day not worked due to sick leave was 
€101.21. The analysis did not taken into account non-healthcare direct costs, that is to say, “out-of-
pocket” costs or costs paid by the patient/family, as these are not recorded in the database and 
patients themselves could not be accessed through the retrospective capture of existing records.  
 
2.5.3 Clinical effectiveness 
 To approximate clinical effectiveness, information was obtained from medical histories 
(clinical protocols) on relative reduction in baseline symptoms (severity of pain or anxiety) using 
the visual analogue scale (VAS) for pain or the Hamilton Rating Scale for Anxiety (HAM-
A)[27,28]. Both scales are implemented in the routine follow up of patients in participant primary 
healthcare centers. The VAS measures the severity of pNP on a scale from 0 (no pain) to 10 (the 
worst pain imaginable). The HAM-A scores responses to 14 questions from 0 to 4 points and 
assesses the severity and frequency of anxiety, with a maximum scoring of 56 points. The scores 
for the two scales (VAS, HAM-A) were compared at the initial and final visits to obtain the 
absolute variation (points) and the relative variation (%) of pain/anxiety severity between the two 
visits (reduction since initial visit). The proportion of patients with anxiety symptoms in remission 
 
 10 
(HAM-A < 7 points) or with mild or no pain (VAS < 4 points) as well as the proportion of 
responders (patients with a ≥ 50% reduction in their initial score for severity of pain or anxiety at 
their final visit) were also obtained. 
 
2.6 Statistical analysis 
 Basic descriptive statistics, such as means and proportions not requiring statistical 
comparisons, are presented in tables by group of interest in the analysis. Analyses requiring 
statistical comparisons were performed using SPSS Version 17 (SPSS Inc., Chicago, USA). 
Standard parametric and non-parametric univariate statistical tests suitable for both the data type 
and the comparison group were performed. In making comparisons across patient subgroups within 
the RedISS sample, maximum likelihood/regression models were applied to isolate the influence of 
each possible explanatory variable on the outcome parameter of interest. These included 
generalized linear models, which are increasingly popular means of modeling health outcome data 
by comparing an outcome measure between two groups while controlling for confounding factors 
[29,30]. A descriptive univariate statistical analysis was performed, and 95% confidence intervals 
(CIs) were obtained to estimate parameters (subjects not lost). The normality of the distribution 
was verified through the Kolmogorov–Smirnov test. The bivariate analysis used analysis of 
variance (ANOVA) tests, the chi-squared test and the Mann–Whitney U test. To measure treatment 
persistence, a survival analysis was performed with the Kaplan–Meier estimator (comparison: log-
rank test). The multivariate models used were as follows: a) analysis of covariance (ANCOVA; 
procedure: estimation of marginal means; Bonferroni adjustment), to correct costs, b) Cox 
proportional hazards model, to correct treatment persistence (dependent variable) and c) multiple 
linear regression, to obtain variables associated with healthcare cost (method: consecutive 
stepwise). The covariables included were as follows: sex, age, general comorbidity (Charlson, 
Resource Utilization Band [RUB]), time since diagnosis, MPR and treatment persistence. 
 
2.7 Reporting guidelines 







From an initial screening of 282,120 subjects ≥ 18 years of age assigned to the sites, 5,850 
patients fulfilling enrollment criteria were recruited. Patients receiving brand-name versus generic 
drug treatment were compared across 4 groups: a) brand-name pregabalin (N = 3,844; 79.1%) vs. 
generic pregabalin (N = 1,016; 20.9%) for pNP; and b) brand-name pregabalin (N = 674; 68.1%) 
vs. generic pregabalin (N = 316; 31.9%) for GAD. Table 2 shows the baseline characteristics of 
patients analyzed. In pNP, the mean age was 59.9 (SD: 13.6) years and 61.3% were women. In 
GAD, the mean age was 58.3 (SD: 16.7) years and 63.9% were women. There was an acceptable 
level of comparability between the brand-name group and the generic group both for pNP and for 
GAD (Table 1). 
Tables 2 and 3 list medication use characteristics, doses administered and concomitant 
medication. For patients with pNP treated with brand-name pregabalin, mean treatment duration 
(6.1 vs. 5.2 months; p < 0.001), MPR (83.6% vs. 78.4%; p<0.001) and persistence after 12 months 
(20.8% vs. 15.6%; p<0.001) were higher than for those treated with generic pregabalin. The 
likelihood of discontinuing to be treated with brand-name pregabalin after 12 months is 
significantly lower than with generic pregabalin; hazard ratio was 0.70 (95% CI: 0.58–0.85, 
p<0.001). The mean daily dose of brand-name vs. generic pregabalin was similar (208.7 vs. 209.8 
mg; p=0.823), while concomitant medication use was significantly lower in the brand-name group 
(1.6 vs. 2.1; p< 0.001), at the expense of NSAIDs, non-narcotic analgesia and opioids. Similar 
results were seen for GAD. With brand-name pregabalin, mean treatment duration (8.6 vs. 7.9 
months; p=0.008), MPR (81.8% vs. 76.5%; p<0.001) and persistence after 12 months (41.2% vs. 
30.7%; p=0.001) were higher than with generic pregabalin. The hazard ratio for discontinuation 
with brand-name pregabalin was 0.63 (95% CI: 0.45-0.84, p<0.001). The mean daily dose of 
brand-name vs. generic pregabalin was similar (232.5 vs. 330.1 mg; p=0.811). The concomitant 
medication group average was lower (2.0 vs. 3.0; p<0.001), respectively, at the expense of all 
groups. Figure 1 lists the Kaplan–Meier curves for treatment persistence both for pNP (A) and for 
GAD (B). These show that persistence was significantly higher for the brand-name drug in 
comparison with the generic drug (p=0.001 and p=0.002 for pNP and GAD, respectively).  
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Table 4 shows a comparison of brand-name vs. generic pregabalin in terms of resource 
utilization and costs by groups. For pNP, the total cost was €7.7 million; of this amount, 71.0% 
corresponded to direct healthcare costs and 29.0% corresponded to non-healthcare costs 
(productivity losses). Subjects being treated with brand-name vs. generic pregabalin used fewer 
healthcare resources, specifically in terms of primary care (PC) visits (10.6 vs. 13.2; p<0.001), 
specialized care visits (2.2 vs. 3.0; p< 0.001) and days of occupational disability (4.1 vs. 6.2; 
p=0.002). The adjusted average annual total cost of subjects being treated with brand-name vs. 
generic pregabalin was lower; €1,500 vs. €2,003, p < 0.001; difference: €–503. This difference was 
maintained for healthcare cost (€1,080 vs. €1,310, p<0.001; difference: €–230) and work 
productivity losses (€420 vs. €692, p=0.003; difference: €–272). For GAD, the total cost was €1.7 
million; of this amount, 63.5% corresponded to direct healthcare costs and 36.4% corresponded to 
non-healthcare costs (productivity losses). Subjects being treated with brand-name vs. generic 
pregabalin used fewer healthcare resources, specifically in terms of PC visits (12.3 vs. 14.3; 
p=0.004) and specialized care visits (1.7 vs. 2.1; p=0.029). Days of occupational disability (5.4 vs. 
8.2; p=0.100) showed no conclusive differences. The adjusted average annual total cost of subjects 
being treated with brand-name vs. generic pregabalin was lower; €1,528 vs. €2,150, p<0.001; 
difference: €–622). Differences were maintained for healthcare cost (€980 vs. €1,301, p<0.001; 
difference: €–321) and work productivity losses (€549 vs. €849, p=0.008; difference: €–300). 
Figure 2 shows total costs by patient age range and group. 
In the multiple linear regression analysis, the total cost of pNP was associated with generic 
pregabalin (β = 0.15), therapeutic non-adherence (β = 0.15), comorbidity (β = 0.12), age (β = 0.10) 
and lower clinical effectiveness (β = 0.10) (p<0.001 in all cases). For GAD, the results were 
similar: the total cost was associated with age (β = 0.21), use of generic pregabalin (β = 0.17), 
therapeutic non-adherence (β = 0.13), lower clinical effectiveness (β = 0.12) and general 
comorbidity (β = 0.09) (p<0.001 in all cases). In pNP, treatment persistence was associated with 
women (odds ratio [OR] =1.6; CI: 1.3–1.9), use of brand-name pregabalin (OR = 1.2; CI: 1.1–1.3), 
clinical effectiveness (OR = 1.2; CI: 1.0–1.4) and age (OR = 1.1; CI: 1.0–1.3) (p<0.003). In GAD, 
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treatment persistence was associated with brand-name pregabalin (OR = 1.8; CI: 1.3–2.7), women 
(OR = 1.5; CI: 1.1–2.1) and age (OR = 1.1; CI: 1.0–1.3) (p<0.01). 
Table 5 lists variation in severity of pain and assessment of anxiety between the start of 
treatment and treatment discontinuation by group. For pNP, no statistically significant differences 
were seen in scores on pain scales at the start visit between the brand-name drug and the generic 
drug (7.3 vs. 7.4 points; p=0.093). Compared to generic treatment, brand-name treatment showed 
an additional reduction in baseline pain: –10.7% (–63.4 vs. –52.7%; p<0.001). For GAD, the 
results were similar: no significant differences were seen in scores on anxiety scales at the visit 
start between the brand-name drug and the generic drug (27.3 vs. 27.7 points; p=0.436). Compared 
to generic treatment, brand-name treatment showed an additional reduction in baseline anxiety:      
–16.7% (–64.4 vs. –47.6%; p<0.001). In patients with remission of symptoms and in responders, 





This paper provides real-world evidence on treatment persistence as well as clinical and 
economic consequences of generic versus brand-name drugs used in routine clinical practice to 
treat pNP and GAD with pregabalin. Findings observed reveal that patients who start treatment 
with brand-name pregabalin versus generic pregabalin, were associated with higher levels of 
treatment adherence, in terms of both medication possession and persistence, and better clinical 
outcomes (reduction in pain and anxiety), resulting in lower resource utilization and healthcare 
costs for the Spanish National Health System. According with Kazis et al.[22], these achieved not 
only statistical significance but also clinical and economic significance (effect size of the difference 
between the two options; Cohen’s d of 0.33 and 0.65 in pain and anxiety, and 0.25 and 0.42 in 
healthcare costs for pNP and GAD, respectively). These findings were consistent both for pNP and 
for GAD, and are congruent with a prior published study conducted by this group also on pNP and 
GAD, although with gabapentin and venlafaxine [32]. However, it should be noted that there are 
few observational studies in real-world conditions in the literature consulted; this makes it difficult 
to compare results, yet highlights the fact that these findings are unique in the field of both 
neuropathic pain and generalized anxiety disorders. It is worth noting its representativeness (as well 
as its potential for application to other healthcare areas), as it includes results from health centers 
belonging to two regions that differ greatly in terms of both geographic location and population, yet 
yielded concordant outcomes (data not shown).  
A great deal of evidence suggests that a generic drug has the same qualitative and quantitative 
composition in terms of active substance and pharmaceutical form, with demonstrated 
bioequivalence (bioavailability studies), in comparison with the reference (brand-name) medicinal 
product. It should be noted that generic versus brand-name drugs may differ in terms of excipient 
composition and outer appearance and that this may result in problems of bioappearance [16,17]. In 
Spain, the entry into the market of these drugs has contributed to a reduction in pharmaceutical 
expenditure in public health; however, at present, both generic and brand-name drugs have the 
same cost of acquisition as there is a reference price system [15]. In view of this, there should be no 
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pharmacological arguments that indiscriminately impede the prescription of brand-name or generic 
drugs.  
At the end of the follow-up period, patients being treated with brand-name for pNP were 
associated with greater persistence (20.8% vs. 15.6%) and MPR (83.6% vs. 78.4%). Similar results 
were reported for GAD patients (persistence: 41.2% vs. 30.7%; MPR: 81.8% vs. 76.5%). In a 
general review of the literature, Wettermark found annual treatment persistence with pregabalin of 
36.3% for GAD and 21.5% for neuropathic pain [33]. Our figures are similar to or perhaps slightly 
higher than those reported (though still low). There might be several explanations for this: a) our 
method of measuring persistence/MPR, b) the fact that we considered the dose indicated by the 
physician at the start of therapy, c) the fact that ours analysis is more recent, d) the fact that these 
patients require care (regularly go in for check-ups), and/or e) the fact that these patients are subject 
to specific follow-up nursing care. As said, our results are consistent with these observations, 
although we have not found any similar findings, with the exception of the above-mentioned with 
gabapentin and venlafaxine [32]. In addition to known reasons for non-adherence, which may be 
intentional (sociodemographic factors, side effects, drug prices, lack of understanding of treatment 
or health status, etc.) or unintentional (failure to remember how to take the medication correctly, 
etc.), the results suggest that administration of a generic drug could be considered an additional 
factor to be taken into account. The appearance of the medicinal product (not measured here) might 
influence our results and affect the worse adherence seen with generic drugs, as shown previously 
[32]. These factors include a different appearance (in terms of color and shape), a lack of certain 
presentations (delayed release or delayed absorption), variability in terms of excipients, a 
copayment effect or even a nocebo effect [34-38]. 
For pNP, patients with brand-name vs. generic pregabalin were associated with lower 
concomitant medication (1.6 vs. 2.1, with 86% vs. 97% using 2 or more concomitant medications, 
p<0.001), total costs (€1,500 vs. 2,003; difference of €503 per patient and treatment) and pain 
reduction (difference of 10.7%). For GAD, concomitant medication (2.0 vs. 3.0, with 71% vs. 83% 
using 2 or more concomitant medications, p<0.001), total cost per patient (€1,528 vs. €2,150; 
difference of €622) and anxiety reduction (16.7%) were also lower. It´s noticeable that opioids use 
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was significantly lower with brand pregabalin both in pNP and GAD subjects, which is important 
in an era of increasing use of such drugs to treat painful health conditions. The (statistically 
significant) lower cost of concomitant medication offset the higher cost of primary medication 
which was higher with the brand-name drug than with the generic drug due to a longer treatment 
duration: €428 vs. €418 in pNP and €438 vs. €448 in GAD. In addition, in the multiple linear 
regression model, the cost (pNP, GAD) was associated with generic pregabalin, non-adherence 
(persistence/MPR) and lower clinical effectiveness. The temporal relationship between non-
adherence, lower clinical effectiveness and greater healthcare resource utilization seems consistent 
in the literature reviewed [18,19,32,39].  
In recent published studies, Lumbreras found that switching between pills of different 
appearances was associated with lower patient adherence to pharmacological treatment and a 
higher uncontrolled blood pressure than no change in pharmacological treatment or change only in 
package but not in pill appearance [19]. Cheng showed that higher suicide rates were reported in 
patients who used generic versus brand-name medicinal products [40]. Leclerc found that patients 
being treated with generic medicinal products had higher rates of adverse effects [41]. Hsu [42], in 
a study to determine the long-term effectiveness of brand-name vs. generic antipsychotics to treat 
schizophrenia, found that higher doses of generic drugs (risperidone and sulpiride) as opposed to 
brand-name drugs were prescribed. Tran reported that the use of generic drugs is associated with a 
reduction in therapeutic monitoring objectives (clinical effectiveness: LDL cholesterol) in treating 
dyslipidemia [43]. Gagne [44], in a prospective study, found that patients who started a treatment 
with generic versus brand-name statins had higher rates of non-adherence and cardiovascular 
episodes. While these data cannot be generalized, they are consistent with other published studies 
[10,32]. 
Arguments in favor of and against generic drugs are not without controversy. By way of 
example, reviews conducted by Kesselheim and Manzoli defended the similar clinical efficacy 
between the brand-name drug and the generic drug [45,46]. Other authors with other designs found 
no differences in terms of outcome variables between brand-name and generic drugs. Unnanuntana 
[47], in a clinical study comparing generic and brand-name alendronic acid (N = 70 per group), 
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found that bone mineral density increased by 2.5% vs. 5.5% and that rates of adverse reactions 
were 35.7% vs. 30.0%, respectively. Mano [48], in a retrospective study, reported that switching 
between brand-name (N = 147) and generic (N = 135) atorvastatin did not affect patients’ treatment 
persistence (85.9% vs. 73.5%) after 180 days of treatment. Loch enrolled 266 patients in his study 
[49]. He concluded that brand-name vs. generic atorvastatin achieved similar results in terms of 
total cholesterol and low-density lipoprotein cholesterol in the clinical management of 
dyslipidemia, although brand-name atorvastatin achieved improvements in high-density lipoprotein 
cholesterol. To our understanding, the following should be assessed: whether these studies obtained 
a suitable sample size (statistical power), where the balance would be between statistical 
significance and clinical significance/repercussions, and when meta-analyses are performed based 
on these studies. However, other authors concluded their studies with a number of 
recommendations. Candido suggested that the use of a generic drug may underestimate the effect 
of adherence of some medicinal products (single dose, delayed absorption)[50]; therefore, 
medicinal products administered to patients with chronic pain should be personalized to better meet 
analgesic needs and ensure patient safety. Fraeyman [51], based on a survey of 1,636 patients, 
recommended highlighting the name of the active substance on drug pack labels to prevent health 
risks, especially in older patients. Colombo concluded that his results are consistent with studies 
supporting the possibility that a change in the appearance of the pack each time a new generic drug 
prescription is supplied may create confusion and reduce patient adherence [52], which may in turn 
influence clinical effectiveness and safety. Our results could support these contributions. Like 
efficacy and bioequivalence between the brand-name drug and the generic drug, our findings 
suggest that changes in the appearance of the drug may have repercussions for patient safety, 
especially in chronic diseases, older patients and/or polymedicated patients. A reduction in 
variability of appearance (image of the drug or similar) among chemically identical medicines or 
implementation of some procedure that would guarantee the patient receives always the same type 
of generic drug could help to promote a lack of treatment discontinuation [53]. 
The potential limitations of this work may be related with retrospective capturing of data, such 
as disease under-recording and potential variability between professionals at the time of treatment 
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(the selection bias on the part of the treating physician when starting a brand-name or generic 
treatment, since this was not done randomly), the system of measurement used for the main 
variables, and the potential existence of a classification bias. In this regard, potentially inaccurate 
diagnostic coding in the diagnosis of pNP or GAD, or the absence of any data that might influence 
the final results (patient socioeconomic status, changes in drug dose prescribed, changes in form 
and presentation of generic drugs, prior acquisition of concomitant medication, lack of recording 
“out-of-pocket” costs, etc.), might be considered a limitation. In addition, the measurement of 
clinical effectiveness (pain or anxiety) could not be obtained in all patients, especially in the final 
period; however, this deficiency was uniformly distributed among the different patient subgroups.  
In conclusion, and taking into account that results should be interpreted with caution, this 
work provide real-world evidence about starting treatment with brand-name pregabalin when 
compared with generic pregabalin for both pNP and GAD health conditions. Results showed brand-
name pregabalin to be associated with higher levels of treatment persistence and adherence, 
resulting in lower healthcare costs, and, at the same time, higher levels of therapeutic effectiveness 
(greater reductions in pain and anxiety).  
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5. Key issues 
 This was a secondary analysis of a retrospective investigation conducted using existing 
electronic medical records (EMRs) that evaluates for the first time the impact on economic 
and clinical consequences of treating two health conditions with pregabalin brand-mane 
(Lyrica
®
) or its generic formulation under real-world routine medical practice. 
 The strength of this paper is that shows how the use of pregabalin brand-name or its generic 
counterpack associates with drug adherence in term of discontinuation and medication 
possesion ratio and how this, after adjusting by covariates, translates into meaningfull 
economic and clinic consequences for the patients and the national health system.  
 A sufficient quantity of data from sixteen healthcare centers from two different regions were 
abstracted and assesed, then, supporting the ability of the findings to be generalized, altholugh  
with caution, to other settings in the country.  
 The potential limitations of this work may be related with retrospective capturing of data, such 
as disease under-recording, errors in disease classification and potential variability between 
healthcare professionals at the time of treatment (the selection bias on the part of the treating 
physician when starting a brand-name or generic treatment). Nonetheless, the multivariate 
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Legend to Figures 
 
Figure 1: Kaplan–Meier curves for persistence and cumulative likelihood of remaining with 
treatment after 12 months of follow-up. 
 
 
Figure 2: Total costs (healthcare and non-healthcare, in EUR) by patient age range and by group. 
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Table 1: Characteristics (demographics and comorbidity) at start of therapy with pregabalin by group and indication. 
 
Groups Peripheral neuropathic pain Generalized anxiety disorder 
Subgroups Brand-name Generic Total 
p 
Brand-name Generic Total 
p 
Number of patients (%) 3,844 (79.1%) 1,016 (20.9%) 4,860 (100%) 674 (68.1%) 316 (31.9%)  990 (100%) 
Sociodemographic characteristics         
Average age (years) 59.7 (13.7) 60.6 (13.3) 59.9 (13.6) 0.066 58.8 (17.4) 57.4 (15.1) 58.3 (16.7) 0.218 
Ranges:  18–44 years 15.6% 13.2% 15.1%  22.1% 19.0% 21.1%  
                45–64 years 43.3% 41.4% 42.9%  38.7% 49.4% 42.1%  
                65–74 years 29.9% 33.8% 30.7%  15.9% 15.5% 15.8%  
                ≥ 75 years 11.2% 11.6% 11.3% 0.054 23.3% 16.1% 21.0% 0.305 
Sex (female) 61.6% 60.0% 61.3% 0.355 63.5% 64.9% 63.9% 0.675 
Pensioners 59.2% 60.8% 59.6% 0.358 55.0% 54.4% 54.8% 0.856 
General comorbidity         
Average diagnoses 6.6 (3.9) 6.9 (3.6) 6.6 (3.8) 0.036 7.3 (4.1) 7.0 (3.8) 7.2 (4.0) 0.276 
Charlson index 0.6 (1.0) 0.7 (1.1) 0.6 (1.0) 0.191 0.6 (0.8) 0.6 (0.8) 0.6 (0.8) 0.998 
Average RUB 2.8 (0.6) 2.9 (0.7) 2.8 (0.7) 0.018 2.9 (0.6) 2.9 (0.7) 2.9 (0.7) 0.647 
1 (very low comorbidity) 4.4% 5.7% 4.7%  3.7% 6.0% 4.4%  
2 (low comorbidity) 17.0% 11.4% 15.9%  11.3% 12.3% 11.6%  
3 (moderate comorbidity) 70.7% 73.2% 71.2%  75.1% 68.4% 72.9%  
4 (high comorbidity) 7.2% 8.2% 7.4%  8.6% 11.7% 9.6%  
5 (very high comorbidity) 0.7% 1.5% 0.9% 0.018 1.3% 1.6% 1.4% 0.174 
Associated comorbidities         
Hypertension 51.8% 51.2% 51.6% 0.754 45.8% 45.8% 45.8% 0.999 
Diabetes mellitus 22.7% 21.7% 22.5% 0.462 16.9% 16.5% 16.8% 0.857 
Dyslipidemia 44.0% 44.4% 44.1% 0.831 45.7% 44.9% 45.5% 0.823 
Obesity 17.8% 17.5% 17.8% 0.824 17.1% 16.7% 17.0% 0.432 
Active smokers 22.3% 22.8% 22.4% 0.759 18.4% 19.9% 18.9% 0.564 
Alcoholism 2.7% 2.8% 2.7% 0.914 4.6% 5.1% 4.7% 0.749 
Ischemic heart disease 7.2% 7.1% 7.2% 0.918 6.7% 6.3% 6.6% 0.837 
Cerebrovascular accident 13.1% 12.3% 12.9% 0.495 12.9% 12.3% 12.7% 0.803 
Organ failure 14.6% 16.7% 15.0% 0.093 12.7% 12.0% 12.6% 0.537 
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Dementia 3.3% 2.2% 3.1% 0.071 4.5% 4.7% 4.5% 0.835 
Depressive syndrome 26.0% 26.3% 26.0% 0.838 47.5% 47.2% 47.4% 0.924 
Malignant neoplasms 13.5% 12.8% 13.3% 0.571 10.7% 11.1% 10.8% 0.853 
Categories of neuropathic pain         
Radiculopathy 49.9% 50.6% 50.0%   ---   
Diabetic neuropathy 22.1% 22.1% 22.1%   ---   
Postherpetic/trigeminal neuralgia 14.0% 12.8% 13.8%   ---   
Other types of neuropathic pain 14.0% 14.5% 14.1% 0.758   ---     
Values expressed as percentage or mean (standard deviation); p: statistical significance between brand-name vs. generic. RUB: resource utilization band. 
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Table 2: Treatment persistence, medication possession ratio and doses administered by group. 
Groups Peripheral neuropathic pain Generalized anxiety disorder 
Subgroups Brand-name Generic Total 
p 
Brand-name Generic Total 
p 
Number of patients (%) 3,844 (79.1%) 1,016 (20.9%) 4,860 (100%) 674 (68.1%) 316 (31.9%) 990 (100%) 
Time since diagnosis (months) 1.7 (1.2) 1.6 (1.2) 1.7 (1.2) 0.605 2.3 (1.4) 2.8 (1.7) 2.4 (1.5) 0.467 
   Median (P25–P75) 2.0 (1.0–2.0) 1.0 (1.0–2.0) 2.0 (1.0–2.0)  2.0 (1.0–4.0) 2.0 (1.0–4.0) 2.0 (1.0–4.0)  
Treatment possession (months) 6.1 (3.4) 5.2 (3.5) 5.9 (3.4) < 0.001 6.9 (3.5) 5.9 (3.6) 6.6 (3.6) < 0.001 
   Median (P25–P75) 5.0 (4.0–8.0) 5.0 (2.0–8.0) 5.0 (4.0–8.0)  6.0 (4.0–11.0) 4.0 (4.0–10.0) 6.0 (4.0–10.0)  
Treatment duration (months) 7.0 (3.4) 6.2 (3.3) 6.8 (3.4) < 0.001 8.6 (3.5) 7.9 (3.6) 8.4 (3.5) 0.008 
   Median (P25–P75) 6.0 (5.0–9.0) 6.0 (3.0–9.0) 6.0 (5.0–10.0)  9.0 (6.0–12.0) 8.0 (6.0–12.0) 9.0 (6.0–12.0)  
Medication Possession Ratio             
   Average 83.6% 78.4% 82.5% < 0.001 81.8% 76.5% 80.1% < 0.001 
   95% CI 82.4–84.8% 75.9–80.9% 81.4–83.6%   78.9–84.7% 71.8–81.2% 77.6–82.6%   
Treatment persistence         
    3 months 89.0% 83.5% 87.9% < 0.001 92.3% 84.5% 89.8% < 0.001 
       Hazard ratio compared to 
brand-name* 
 0.62 (0.51–0.76)  < 0.002  0.45 (0.30–0.69)  < 0.001 
    6 months 56.8% 52.8% 56.0% 0.020 80.0% 75.9% 78.7% 0.150 
       Hazard ratio compared to 
brand-name* 
 0.83 (0.72–0.96)  0.010  0.78 (0.57–1.08)  0.148 
    9 months 35.5% 28.4% 34.0% < 0.001 55.3% 44.9% 52.0% 0.002 
       Hazard ratio compared to 
brand-name* 
 0.71 (0.61–0.83)  0.002  0.66 (0.50–0.86)  0.004 
   12 months 20.8% 15.6% 19.7% < 0.001 41.2% 30.7% 37.9% 0.001 
       Hazard ratio compared to 
brand-name* 
  0.70 (0.58–0.85)   0.001   0.63 (0.45–0.84)   0.002 
Pregabalin dosage (mg/day) 208.7 (142.7) 209.8 (140.2) 209.0 (142.2) 0.823 232.5 (151.3) 230.1 (127.8) 231.7 (144.1) 0.811 
     75 mg/day 3.9% 4.7% 4.1%  0.1% 1.6% 0.5%  
   100 mg/day 8.6% 7.0% 8.2%  0.6% 1.6% 0.9%  
   150 mg/day 63.6% 62.6% 63.4%  69.7% 57.3% 65.8%  
   300 mg/day 14.0% 16.2% 14.4%  16.9% 32.0% 21.7%  
   600 mg/day 10.0% 9.4% 9.9% 0.132 12.8% 7.6% 11.1% < 0.001 
Values expressed as percentage or mean (SD: standard deviation); p: brand-name vs. generic; CI: confidence interval. 




Table 3: Concomitant medication by group. 
Groups Peripheral neuropathic pain Generalized anxiety disorder 
Subgroups Brand-name Generic Total 
p 
Brand-name Generic Total 
p 
Number of patients (%) 3,844 (79.1%) 1,016 (20.9%) 4,860 (100%) 674 (68.1%) 316 (31.9%)  990 (100%) 
Concomitant medication (average) 1.6 (1.0) 2.1 (1.2) 1.7 (1.1) < 0.001 2.0 (1.0) 3.0 (1.0) 2.0 (1.0) < 0.001 
   1 13.9% 3.1% 11.6%  28.9% 17.4% 25.3%  
   2 23.7% 22.8% 23.5%  21.8% 22.2% 21.9%  
   3 28.3% 36.3% 30.0%  26.9% 33.5% 29.0%  
   4 22.7% 24.7% 23.1%  12.2% 22.8% 15.6%  
   5 9.8% 11.0% 10.0% < 0.001 2.4% 3.5% 2.7% < 0.001 
Concomitant medication groups         
   NSAIDs 48.3% 60.0% 50.7% < 0.001 44.7% 54.7% 47.9% 0.003 
   Analgesics 71.0% 80.6% 73.0% < 0.001 41.8% 55.4% 46.2% < 0.001 
   Anxiolytics 17.2% 19.0% 17.6% 0.193 72.4% 87.7% 77.3% < 0.001 
   Antidepressants 32.8% 34.1% 33.1% 0.461 41.8% 54.7% 46.0% < 0.001 
   Opioids 25.9% 30.3% 26.9% 0.005 12.9% 18.4% 14.6% 0.031 





Table 4: Resource utilization and associated costs (€) by group. 
 
Groups Peripheral neuropathic pain Generalized anxiety disorder 
Subgroups Brand-name Generic Total 
P 
Brand-name Generic  Total 
p 
Number of patients (%) 3,844 (79.1%) 1,016 (20.9%) 4,860 (100%) 674 (68.1%) 316 (31.9%)  990 (100%) 
Resource utilization         
Medical visits (primary care) 10.6 (5.5) 13.2 (4.6) 11.1 (5.4) <0.001 12.3 (10.3) 14.3 (9.6) 12.9 (10.1) 0.004 
Laboratory tests 1.1 (1.2) 1.3 (1.4) 1.1 (1.2) <0.001 0.8 (1.1) 1.2 (1.5) 0.9 (1.2) <0.001 
Conventional radiology 0.8 (1.0) 1.0 (1.1) 0.8 (1.1) <0.001 0.5 (0.9) 1.6 (1.7) 0.8 (1.3) <0.001 
Complementary tests 0.3 (0.6) 0.3 (0.6) 0.3 (0.6) 0.306 0.1 (0.6) 0.3 (0.7) 0.2 (0.6) <0.001 
Days of hospitalization 0.2 (1.3) 0.3 (2.0) 0.2 (1.4) 0.010 0.1 (0.8) 0.3 (1.1) 0.2 (0.9) 0.020 
Medical visits (hospital) 2.2 (3.3) 3.0 (3.2) 2.4 (3.3) <0.001 1.7 (3.1) 2.1 (2.9) 1.8 (3.1) 0.029 
Day hospital sessions 0.2 (1.1) 0.3 (1.8) 0.2 (1.3) <0.001 0.1 (0.4) 0.2 (1.1) 0.1 (0.7) <0.001 
Emergency visits (hospital) 0.4 (0.7) 0.8 (0.9) 0.5 (0.7) <0.001 0.5 (0.8) 1.1 (1.1) 0.7 (1.0) <0.001 
Days of occupational disability 4.1 (18.9) 6.2 (22.6) 4.6 (19.8) 0.002 5.4 (24.7) 8.2 (23.5) 6.3 (24.3) 0.100 
Unadjusted costs         
Healthcare costs 1,079 (854) 1,328 (1,126) 1,131 (923) <0.001 1,013 (728) 1,311 (933) 1,108 (811) <0.001 
   Costs in primary care 722 (437) 782 (332) 735 (418) <0.001 753 (410) 845 (433) 783 (420) 0.001 
        Medical visits 245 (127) 306 (107) 258 (126) <0.001 285 (238) 331 (222) 300 (234) 0.004 
        Laboratory tests 24 (26) 29 (31) 25 (27) <0.001 18 (24) 27 (33) 21 (28) <0.001 
        Conventional radiology 15 (19) 18 (21) 16 (19) <0.001 9 (16) 29 (32) 15 (24) <0.001 
        Complementary tests 10 (23) 11 (23) 10 (23) 0.306 4 (22) 10 (26) 6 (24) <0.001 
        Concomitant medication
1
 182 (371) 217 (254) 189 (350) 0.005 171 (190) 215 (180) 185 (188) <0.001 
        Baseline medication 246 (116) 201 (118) 236 (118) <0.001 267 (177) 233 (192) 256 (183) 0.006 
   Costs in specialized care 357 (706) 547 (1028) 396 (788) <0.001 260 (503) 466 (685) 326 (575) <0.001 
        Days of hospitalization 90 (534) 145 (834) 102 (609) 0.010 45 (327) 106 (483) 65 (384) 0.020 
        Day hospital sessions 202 (308) 272 (299) 217 (307) <0.001 155 (287) 197 (266) 168 (281) 0.029 
        Medical visits 19 (132) 41 (227) 23 (157) <0.001 7 (56) 31 (136) 15 (90) <0.001 
        Emergency visits 46 (79) 89 (107) 55 (88) <0.001 53 (96) 132 (125) 78 (113) <0.001 
Non-healthcare costs 
(productivity loss) 
418 (1,915) 632 (2,288) 463 (2,000) 0.002 548 (2,496) 824 (2,371) 636 (2,459) 0.100 





   Difference*    Difference*  
Healthcare costs 1,080 1,310 –230 < 0.001 980 1,301 –321 0.001 
      95% CI 1,051–1,110 1,254–1,367   921–1,038  1,214–1,387   
Non-healthcare costs 
(productivity loss) 
420 692 –272 0.003 549 849 –300 0.008 
      95% CI 356–484 569–817   357–741 565–1,132   
Total costs (€) 1,500 2,003 –503 < 0.001 1,528 2,150 –622 < 0.001 
      95% CI 1,428–1,573 1,864–2,143     1,322–1,734 1,845–2,454     
Values expressed as mean (SD: standard deviation); p: brand-name vs. generic; CI: confidence interval. *Difference: brand-name versus generic. 
1 Concomitant medication (non-steroidal anti-inflammatory drugs, analgesics, anxiolytics, antidepressants and opioids).  




Table 5: Variation in pain severity and anxiety assessment between the start of treatment and treatment discontinuation by group. 
 
Subgroups Brand-name Generic 
p 
Number of patients (%) 3,844 (79.1%) 1,016 (20.9%) 
Peripheral neuropathic pain (VAS)*    
Start of treatment 7.3 (1.2) 7.4 (1.2) 0.093 
Treatment discontinuation 3.0 (1.1) 4.5 (1.2) < 0.001 
Absolute variation (score) –4.3 (1.3) –3.9 (1.3) < 0.001 
Relative variation (%) –63.4% –52.7% < 0.001 
Remission (< 4 points in a 0-10 scored scale) 55.0% 46.7% 
< 0.001 
      95% CI 53.4%–56.6% 43.6%–49.7% 
Responders (reduction ≥ 50% of baseline score) 59.2% 48.4% 
< 0.001 
      95% CI 57.7%–60.8% 45.4%–51.5% 
Subgroups Brand-name Generic 
p 
Number of patients (%) 674 (68.1%) 316 (31.9%) 
Generalized anxiety disorder (HAM-A)*   
Start of treatment 27.3 (6.9) 27.7 (6.7) 0.436 
Treatment discontinuation 9.7 (4.8) 14.5 (5.0) < 0.001 
Absolute variation (score) –17.6 (6.0) –13.2 (5.6) < 0.001 
Relative variation (%) –64.4% –47.6% < 0.001 
Remission (< 7 points in a 0-56 scored scale) 58.6% 48.7% 
< 0.001 
      95% CI 54.9%–62.3% 43.2%–53.3% 
Responders (reduction ≥ 50% of baseline score) 64.6% 47.2% 
< 0.001 
      95% CI 60.9%–68.1% 41.7%–52.7% 
Values expressed as mean (SD: standard deviation); p: brand-name vs. generic. CI: confidence interval. 
VAS: visual analogue scale for pain. HAM-A: Hamilton Rating Scale for Anxiety. 
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